These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1592 related items for PubMed ID: 16786040

  • 1. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [Abstract] [Full Text] [Related]

  • 2. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 4. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
    Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1048-55. PubMed ID: 15001244
    [Abstract] [Full Text] [Related]

  • 6. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.
    J Urol; 2005 Sep 15; 174(3):882-7. PubMed ID: 16093980
    [Abstract] [Full Text] [Related]

  • 7. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S.
    J Clin Oncol; 2005 Sep 20; 23(27):6561-8. PubMed ID: 16170164
    [Abstract] [Full Text] [Related]

  • 8. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.
    Int J Radiat Oncol Biol Phys; 2006 Dec 01; 66(5):1430-9. PubMed ID: 16765527
    [Abstract] [Full Text] [Related]

  • 9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 10. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 01; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 11. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE, Galalae R, Demanes J, Harsolia A, Meldolesi E, Nürnberg N, Schour L, Martinez A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1474-82. PubMed ID: 15964706
    [Abstract] [Full Text] [Related]

  • 12. Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
    Vargas CE, Demanes J, Boike TP, Barnaba MC, Skoolisariyaporn P, Schour L, Gustafson GS, Gonzalez J, Martinez AA.
    Am J Clin Oncol; 2006 Oct 01; 29(5):451-7. PubMed ID: 17023778
    [Abstract] [Full Text] [Related]

  • 13. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: what should we expect?
    Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA.
    Cancer; 2004 Mar 15; 100(6):1283-92. PubMed ID: 15022298
    [Abstract] [Full Text] [Related]

  • 14. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study.
    Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, Krauss DJ, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):416-23. PubMed ID: 16879929
    [Abstract] [Full Text] [Related]

  • 15. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1140-50. PubMed ID: 16198506
    [Abstract] [Full Text] [Related]

  • 16. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis.
    Sylvester J, Blasko JC, Grimm PD, Meier R, Cavanagh W.
    Mol Urol; 2000 Mar 15; 4(3):155-9;discussion 161. PubMed ID: 11062369
    [Abstract] [Full Text] [Related]

  • 17. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups?
    Galalae RM, Martinez A, Nuernberg N, Edmundson G, Gustafson G, Gonzalez J, Kimming B.
    Strahlenther Onkol; 2006 Mar 15; 182(3):135-41. PubMed ID: 16520907
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.